| Name | Title | Contact Details |
|---|---|---|
Anju Nagpal |
DIRECTOR - R&D FINANCE | Profile |
Jerald Novak |
Senior Director - Human Resources | Profile |
Amanda Sorrento |
Human Resources Director - Research and Development - Corporate Strategy - Corporate Development and Early Pipeline Programs | Profile |
Andrea Blake |
Director - Human Resources -Global Quality | Profile |
Kelly Clements |
Director - Employee Relations | Profile |
Biotech and Life Science News, Jobs, and Events for the BioHealth Capital Region - Maryland, D.C., and Virginia. BioBuzz: Be More Connected.
Genosco is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Providence is a clinical-stage biotechnology company pioneering mRNA therapeutics and vaccines with a focus on infectious diseases and oncology. Initially founded as a cancer vaccines company in 2015, in response to a worldwide need for a COVID-19 vaccine, Providence expanded its focus beyond oncology therapies to develop an mRNA vaccine for COVID-19. Providence works with multiple industry collaborators, universities, nongovernmental agencies and multiple arms of the Government of Canada to discover and develop vaccines and treatments for infectious diseases and cancer. This has resulted in the development of an mRNA vaccine platform that includes a proprietary design algorithm and proprietary, scalable manufacturing processes.
Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.
Ribon Therapeutics is a biotech company focused on developing first-in-class therapeutics targeting mono(ADP-ribosyl)ating PARPs for cancer.